10x Genomics, Inc.

NasdaqGS:TXG Stock Report

Market Cap: US$1.7b

10x Genomics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:TXG Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Nov 24SellUS$79,485Benjamin HindsonIndividual5,807US$13.69
22 Nov 24SellUS$91,612Serge SaxonovIndividual6,693US$13.69
22 Aug 24SellUS$66,710Justin McAnearIndividual2,961US$22.53
22 Aug 24SellUS$98,027Benjamin HindsonIndividual4,351US$22.53
22 Aug 24SellUS$152,053Serge SaxonovIndividual6,749US$22.53
22 May 24SellUS$118,529Serge SaxonovIndividual4,877US$24.30
22 May 24SellUS$71,355Justin McAnearIndividual2,936US$24.30
22 May 24SellUS$99,329Benjamin HindsonIndividual4,087US$24.30
04 Mar 24SellUS$205,021Serge SaxonovIndividual4,660US$44.00
22 Feb 24SellUS$86,432Justin McAnearIndividual1,865US$46.34
22 Feb 24SellUS$130,737Serge SaxonovIndividual2,821US$46.34
22 Feb 24SellUS$121,098Benjamin HindsonIndividual2,613US$46.34

Insider Trading Volume

Insider Buying: TXG insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of TXG?
Owner TypeNumber of SharesOwnership Percentage
State or Government45,4750.0376%
General Public3,946,1173.26%
Individual Insiders10,131,8428.37%
Institutions106,931,01488.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.

Top Shareholders

Top 25 shareholders own 79.76% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.1%
FMR LLC
18,238,630US$256.1m2%0.01%
9.06%
The Vanguard Group, Inc.
10,972,930US$154.1m7.69%no data
8.88%
ARK Investment Management LLC
10,750,345US$150.9m15.4%1.06%
5.63%
BlackRock, Inc.
6,815,370US$95.7m6.61%no data
5.26%
Nikko Asset Management Co., Ltd.
6,373,212US$89.5m3.75%0.03%
3.86%
T. Rowe Price Group, Inc.
4,677,678US$65.7m-7.13%0.01%
3.6%
Morgan Stanley Investment Management Inc.
4,353,634US$61.1m10.5%0.05%
3.33%
Serge Saxonov
4,028,605US$56.6m0.08%no data
3.13%
VR Adviser, LLC
3,790,422US$53.2m0%2.68%
2.67%
Benjamin Hindson
3,237,278US$45.5m-0.03%no data
2.3%
Citadel Advisors LLC
2,779,970US$39.0m731%0.04%
2.02%
John Stuelpnagel
2,441,337US$34.3m0%no data
1.81%
Brown Capital Management, LLC
2,195,319US$30.8m-11.6%0.41%
1.79%
UBS Asset Management AG
2,167,739US$30.4m4.32%no data
1.5%
Geode Capital Management, LLC
1,815,710US$25.5m2.41%no data
1.45%
State Street Global Advisors, Inc.
1,750,643US$24.6m7.13%no data
1.25%
Deerfield Management Company, L.P. Series C
1,508,943US$21.2m153%0.37%
1.21%
Point72 Asset Management, L.P.
1,466,227US$20.6m0%0.05%
1.17%
Voloridge Investment Management, LLC
1,414,804US$19.9m-1.75%0.07%
1.08%
Morgan Stanley, Investment Banking and Brokerage Investments
1,310,779US$18.4m27.6%no data
0.82%
Norges Bank Investment Management
991,051US$13.9m0%no data
0.79%
Soleus Capital Management, L.P.
951,000US$13.4m32.3%1.02%
0.76%
Millennium Management LLC
918,757US$12.9m-32.5%0.01%
0.67%
Eaton Vance Management
811,894US$11.4m0.79%no data
0.66%
Capital Research and Management Company
793,300US$11.1m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

10x Genomics, Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Luke SergottBarclays
Michael RyskinBofA Global Research